HKSE · 0288.HK
WH Group Limited
HK$6.32+HK$0.08 (+1.28%)
WH Group Limited’s quoted price sits in the lower half of its reported 52-week range, 41.74% below the high.
Loading market information…
HKSE · 1112.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 02:02 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Health and Happiness (H&H) International Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 1.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Health and Happiness (H&H) International Holdings Limited’s forward annual dividend is HK$1.64 per share, paid semi-annual. The forward yield is 6.84% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Health and Happiness (H&H) International Holdings Limited’s next earnings report is currently expected on Mar 23, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Health and Happiness (H&H) International Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
As an investment holding entity, Health and Happiness (H&H) International Holdings Limited specializes in the global production and distribution of nutritional and care products designed for families and infants. Its offerings are categorized into several key segments. The Infant Formulas division crafts nutritional formulas for children up to age seven, alongside specialized milk products for pregnant and breastfeeding women. The Probiotic Supplements division provides various forms of probiotics, including sachets, capsules, and tablets, catering to the needs of babies, children, and expecting mothers. Within its Adult Nutrition and Care Products segment, H&H develops and markets a range of items such as vitamins, general health supplements, skincare solutions, and sports nutrition for grown-ups. Complementing its infant offerings, the Other Pediatric Products segment focuses on manufacturing dried baby foods, additional nutritional supplements, and general baby care items. Furthermore, its Pet Nutrition and Care segment creates pet food, health-enhancing supplements, and bone broth products for animals. Beyond these core product lines, the company's activities extend to research, development, and processing of diverse ingredients like meat, fruit, and vegetable powders, as well as candies. It actively researches, develops, manufactures, and sells specialized nutritional foods, manages the marketing and distribution of organic baby foods, and handles the wholesale, retail, import, and export of infant nutritional and personal care products. H&H also engages in the trading and sale of adult vitamins, health supplements, probiotic skincare, and sports nutrition items, while offering online sales platforms, software and IT solutions, and packaging services. Its extensive product portfolio is marketed under well-known brands such as Biostime, Swisse, Aurelia, Zesty Paws, Solid Gold, Dodie, Good Gout, Aurelia London, and CBII. Established in 1999, the company adopted its current name, Health and Happiness (H&H) International Holdings Limited, in June 2017, having previously operated as Biostime International Holdings Limited. Headquartered in Quarry Bay, Hong Kong, H&H functions as a subsidiary of Biostime Pharmaceuticals (China) Limited.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| HK$7.69B+2.58% vs estimate |
| Q2 2023 | Jun 30, 2023 | HK$1.02+34.92% vs estimate | HK$7.55B+8.35% vs estimate |
|---|
| Q4 2022 | Mar 21, 2023 | HK$0.44-34.69% vs estimate | HK$7.72B-0.44% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$6.32+HK$0.08 (+1.28%)
WH Group Limited’s quoted price sits in the lower half of its reported 52-week range, 41.74% below the high.
HK$5.87+HK$0.21 (+3.71%)
Budweiser Brewing Company APAC Limited’s quoted price sits in the lower half of its reported 52-week range, 29.7% below the high.
HK$19.37+HK$1.22 (+6.72%)
China Mengniu Dairy Company Limited’s quoted price sits in the upper half of its reported 52-week range, 1.53% below the high.
HK$2.52+HK$0.01 (+0.4%)
China Feihe Limited’s quoted price sits in the lower half of its reported 52-week range, 43.86% below the high.
HK$1.05-HK$0.01 (-0.48%)
Ausnutria Dairy Corporation Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.17% below the high.
HK$1.63+HK$0.02 (+0.93%)
JBM (Healthcare) Limited’s quoted price sits in the lower half of its reported 52-week range, 47.75% below the high.
HK$0.70+HK$0.01 (+0.72%)
Numans’s quoted price sits in the upper half of its reported 52-week range, 16.27% below the high.
HK$0.33+HK$0.02 (+4.84%)
Hin Sang Group (International) Holding Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 21.69% below the high.
